A Randomized, Double-Blind, Placebo Controlled, Multicenter, 12-week Phase 3 Study to Evaluate Efficacy and Safety of ALS-L1023 Tablet in Patients With Abdominal Obesity of Metabolic Syndrome

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Multicenter, 12-week Phase 3 Study to Evaluate Efficacy and Safety of ALS-L1023 Tablet in Patients With Abdominal Obesity of Metabolic Syndrome

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs ALS L1023 (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 10 Oct 2016 Status changed from recruiting to discontinued.
    • 11 Jun 2013 New source identiofied and integrated: ClinicalTrials.gov record.
    • 11 Jun 2013 Status changed from planning to recruiting as reported by the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top